Business & Finance
BIOCORP incurs lower loss of EUR50,000 in H1 2021
28 September 2021 -

French medical company BIOCORP (Paris:ALCOR) disclosed on Monday its loss of EUR50,000 for the half-year as of 30 June 2021.

This marks an improvement in earnings when compared to higher loss of EUR79 ,000 a year earlier, mainly resulting from the interest on bonds.

Operating revenues remained stable at EUR3.88m for the half-year as of 30 June 2021.

For the half-year as of 30 June 2021, the operating expenses was EUR5.214, 000, up 9.7% year-on-year over the EUR4.752,000 during H1 2020 due to the increase in salaries and expenses.

Login
Username:

Password: